Literature DB >> 17080017

Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas.

L M Kovalevska1, O V Yurchenko, L M Shlapatska, G G Berdova, S V Mikhalap, J Van Lint, S P Sidorenko.   

Abstract

AIM: To study the PKD2 expression, autophosphorylation and localization in reactive lymph nodes and tumors of lymphoid tissues.
MATERIALS AND METHODS: Specific antibodies, which recognize PKD1/2 or PKD2 and autophosphorylated PKD1/2, were used for immunohistochemical and biochemical studies of tonsils, reactive lymph nodes, tumor samples of non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL).
RESULTS: Immunohistochemical and biochemical analysis of PKD1 and PKD2 expression showed PKD2 expression in tonsils, reactive lymph nodes and tumor tissues from patients with NHL and HL. Furthermore, we were not able to reveal PKD1 expression in studied lymphoid tissues. In tonsils and reactive lymph nodes the PKD2 expression was detected in T and B cell zones with highest level in germinal centers of lymphoid follicles and the maximum level of autophosphorylation in the light zones of the germinal centers. We found that low level of PKD2 expression and autophosphorylation was characteristic feature for mantle cell lymphomas, Burkitt's lymphomas, and in 50% of CLL/small lymphocytic lymphomas. Lymphoma cells of germinal center origin and with activated B cell phenotype (diffuse large B cell lymphomas, HL) and anaplastic large cells lymphoma demonstrated the high level of PKD2 expression and autophosphorylation.
CONCLUSIONS: The level of PKD2 expression and autophosphorylation in neoplastic cells corresponds to the expression pattern of this kinase in their normal analogs, and to the level of cell differentiation and activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17080017

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  7 in total

Review 1.  Protein kinase D as a potential new target for cancer therapy.

Authors:  Courtney R LaValle; Kara M George; Elizabeth R Sharlow; John S Lazo; Peter Wipf; Q Jane Wang
Journal:  Biochim Biophys Acta       Date:  2010-05-24

2.  Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.

Authors:  Ninel Azoitei; Alexander Kleger; Nina Schoo; Dietmar Rudolf Thal; Cornelia Brunner; Ganesh Varma Pusapati; Alina Filatova; Felicitas Genze; Peter Möller; Til Acker; Rainer Kuefer; Johan Van Lint; Heinrich Baust; Guido Adler; Thomas Seufferlein
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

3.  Kinase-independent feedback of the TAK1/TAB1 complex on BCL10 turnover and NF-κB activation.

Authors:  Miguel E Moreno-García; Karen Sommer; Hector Rincon-Arano; Michelle Brault; Jun Ninomiya-Tsuji; Lydia E Matesic; David J Rawlings
Journal:  Mol Cell Biol       Date:  2013-01-07       Impact factor: 4.272

4.  HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization.

Authors:  Ninel Azoitei; Kristina Diepold; Cornelia Brunner; Arefeh Rouhi; Felicitas Genze; Alexander Becher; Hans Kestler; Johan van Lint; Gabriela Chiosis; John Koren; Stefan Fröhling; Claudia Scholl; Thomas Seufferlein
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

Review 5.  Protein kinase D signaling in cancer: A friend or foe?

Authors:  Adhiraj Roy; Jing Ye; Fan Deng; Qiming Jane Wang
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-05-31       Impact factor: 10.680

6.  High PKD2 predicts poor prognosis in lung adenocarcinoma via promoting Epithelial-mesenchymal Transition.

Authors:  Zhaofei Pang; Yu Wang; Nan Ding; Xiaowei Chen; Yufan Yang; Guanghui Wang; Qi Liu; Jiajun Du
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

7.  Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia.

Authors:  Stéphane Saint-Georges; Maude Quettier; Marouane Bouyaba; Stéphanie Le Coquil; Vanessa Laurienté; Lionel Guittat; Vincent Lévy; Florence Ajchenbaum-Cymbalista; Nadine Varin-Blank; Christine Le Roy; Dominique Ledoux
Journal:  Oncotarget       Date:  2016-07-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.